Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1989
Monoclonal antibodies to the apical chloride channel in Necturus gallbladder inhibit the chloride conductanceA L Finn, L M Tsai, R J Falk
Alimentary Pharmacology & Therapeutics|December 1, 1991
Effects of ranitidine, given t.d.s., on intragastric and oesophageal pH in patients with gastrooesophageal refluxJ Russell, W C Orr, T Wilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapyL H Einhorn, C Nagy, K Werner, et al.
The American Journal of Physiology|July 1, 1992
Regulation of an epithelial chloride channel by direct phosphorylation and dephosphorylationA L Finn, M L Gaido, M Dillard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimensL X Cubeddu, I S Hoffman, N T Fuenmayor, et al.
Gastroenterology|February 24, 2001
Sucrase-isomaltase is an adenosine 3',5'-cyclic monophosphate-dependent epithelial chloride channelA L Finn, E V Kuzhikandathil, G S Oxford, et al.
The New England Journal of Medicine|March 22, 1990
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomitingL X Cubeddu, I S Hoffmann, N T Fuenmayor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2009
Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled studyR Rauck, J North, L N Gever, et al.
Alimentary Pharmacology & Therapeutics|December 1, 1988
The timing of evening meal and ranitidine administration--effects on patterns of 24 hour intragastric acidityW C Orr, A L Finn, M Allen, et al.
American Journal of Clinical Oncology|August 1, 1991
Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapyJ D Hainsworth, G A Omura, A Khojasteh, et al.
Pageof 5